<DOC>
	<DOCNO>NCT00527605</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , six-month parallel-group study assess efficacy safety dutasteride 0.5mg daily Chinese patient Benign Prostatic Hyperplasia ( BPH ) , follow 12-month open-label treatment phase</brief_summary>
	<brief_title>Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Inclusion : Clinical diagnosis BPH AUASI &gt; =12 [ American Urological Association Symptom Index ] Qmax &gt; 5ml/sec &lt; =15ml/sec minimum void volume &gt; =125ml Prostate volume &gt; =30cm ( 3 ) Exclusion : Post void residual volume &gt; 250ml History evidence prostate cancer Total serum PSA &lt; 1.5ng/ml &gt; 10.0ng/ml ( Prostate specific antigen ) Previous prostatic surgery invasive procedure treat BPH . History AUR ( Acute Urinary Retention ) within 3 month History flexible/rigid cystoscopy instrumentation urethra within 7 day Any cause BPH , may judgement investigator , result urinary symptom change flow rate History hepatic impairment abnormal liver function test Use 5areductase inhibitor , drug antiandrogenic property drug note gynaecomastia effect , could affect prostate volume , within past 6 month throughout study Use alphareceptor blocker within 2 week throughout study . Use phytotherapy BPH within 2 week and/or predict need phytotherapy study . Concurrent use anabolic steroid Use alphaadrenergic agonist cholinergics within 48 hour prior uroflowmetry assessment . Hypersensitivity 5areductase inhibitor chemicallyrelated drug . Actively try procreate unwilling wear condom intercourse woman childbearing potential duration participation study 16 week follow treatment . History current evidence drug alcohol abuse within previous 12 month . History illness opinion investigator might confound result study pose additional risk patient . Any unstable , serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening visit ; uncontrolled diabetes peptic ulcer disease uncontrolled medical management . History renal insufficiency , serum creatinine &gt; 1.5xULN ( Upper Limit Normal ) Participation investigational market drug trial within 30 day course study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>placebo control</keyword>
	<keyword>Chinese</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>Randomized</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Double blind</keyword>
</DOC>